Navigation Links
ISS Recommends Hologic Stockholders Vote 'FOR' Merger With Cytyc

Updates Recommendation to Support Amendment to Hologic's 1999 Equity

Incentive Plan

BEDFORD, Mass., Oct. 11 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a leading provider of state-of-the-art diagnostic and digital imaging systems directed towards women's health, today announced that ISS, the leading independent proxy advisory service, recommends that Hologic stockholders vote "FOR" the Company's proposed merger with Cytyc Corporation (Nasdaq: CYTC).

In addition, ISS has updated its recommendation with regard to a proposed amendment to Hologic's 1999 Equity Incentive Plan to increase the number of shares available for grant thereunder and recommends that Hologic stockholders vote "FOR" the proposed amendment.

"We appreciate the support that ISS has given to our combination with Cytyc and to Hologic's stock plan," said Jack Cumming, Hologic's Chairman and Chief Executive Officer. "Together with Cytyc, we will be a global leader in women's healthcare. We look forward to realizing the many benefits this combination creates."

As previously announced, on May 20, 2007, Hologic and Cytyc entered into a definitive agreement to combine the two companies in a cash and stock transaction, under which Cytyc stockholders would receive 0.52 of a share of Hologic common stock and $16.50 in cash for each share of Cytyc common stock they own for a total consideration of approximately $6.2 billion.

A special meeting of the stockholders of Hologic to consider and vote upon the transactions contemplated by the proposed merger with Cytyc, including the proposed amendment to Hologic's 1999 Equity Incentive Plan to increase the number of shares available for grant thereunder, has been scheduled for October 18, 2007 at 9:00 a.m., local time, at Hologic's headquarters at 35 Crosby Drive, Bedford, Massachusetts. Hologic stockholders of record as of the close of business on August 22, 2007 will be entitled to vote at the special meeting.

Stockholders are encouraged to read the Company's definitive proxy materials in their entirety as they provide, among other things, a detailed discussion of the process that led to the proposed merger and the reasons behind the Board of Directors' unanimous recommendation that stockholders vote FOR the approval of the transactions contemplated by the proposed merger with Cytyc, including the proposed amendment to Hologic's 1999 Equity Incentive Plan to increase the number of shares available for grant thereunder.

Stockholders who have questions about the merger or need assistance in submitting their proxy or voting their shares should contact the Company's proxy solicitor, MacKenzie Partners, Inc. toll-free at (800) 322-2885 or collect at (212) 929-5500 or at

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic and medical imaging systems dedicated to serving the healthcare needs of women, and a leading developer of innovative imaging technology for digital radiography and breast imaging. Hologic's core business units are focused on mammography and breast biopsy, osteoporosis assessment, and mini C- arm and extremity MRI imaging for orthopedic applications.

Forward-Looking Statements

Information set forth in this communication contains forward-looking statements, which involve a number of risks and uncertainties, including statements involving the anticipated benefits of the proposed transaction. Hologic cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Without limiting the foregoing, Hologic cannot guarantee that the transaction will be completed on a timely basis if at all. Among other things, the transaction is subject to approval of both companies' stockholders as well as other customary closing conditions.

The risks and uncertainties included above are not exhaustive. The Registration Statement on Form S-4 (File No. 333-144238), the annual reports on Form 10-K, the quarterly reports on Form 10-Q, current reports on Form 8-K and other documents Hologic and Cytyc have filed with the SEC contain additional factors that could impact the timing or completion of the transaction. The parties expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in the parties expectations or any change in events, conditions or circumstances on which any such statement is based.

Important Information for Investors and Stockholders

Hologic and Cytyc filed an amended joint proxy statement/prospectus with the SEC in connection with the proposed merger on September 7, 2007. Hologic urges investors and stockholders to read the joint proxy statement/prospectus and any other relevant documents filed by either party with the SEC because they contain important information.

Investors and stockholders are able to obtain the joint proxy statement/prospectus and other documents filed with the SEC free of charge at the website maintained by the SEC at . In addition, documents filed with the SEC by Hologic will be available free of charge on the investor relations portion of the Hologic website at .

Participants in the Solicitation

Hologic, and certain of its directors and executive officers, may be deemed participants in the solicitation of proxies from the stockholders of Hologic in connection with the merger. The names of Hologic's directors and executive officers and a description of their interests in Hologic are set forth in the proxy statement for Hologic's 2006 annual meeting of stockholders, which was filed with the SEC on January 25, 2007. Investors and stockholders can obtain more detailed information regarding the direct and indirect interests of Hologic's directors and executive officers in the merger by reading the definitive joint proxy statement.

Hologic Contacts:

Glenn Muir, Executive Vice President and Chief Financial Officer


Frances Crecco, Investor Relations


Additional Contacts:

Joele Frank, Andrea Priest

Joele Frank, Wilkinson Brimmer Katcher


SOURCE Hologic, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
2. FDA recommends new Lead level in candies
3. Journal Recommends How To Improve The Performance Of Health Workers
4. WHO says MMR vaccine is safe and recommends MMR Jab to all children’
5. FDA Recommends Strong Warning Labels On the ADHD Drugs
6. NHS Recommends Further Cost Cutting Measures
7. European Medicines Agency (EMEA) Recommends Herceptin For Early Stage Breast Cancer
8. Psychological consequence of terrorist attacks
9. Breast Cancer Surgery Causes Psychological problems
10. Gastrointestinal Complaint to be dealt Psychologically
11. Prolonged survival not assured by psychological therapies for cancer patients
Post Your Comments:
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... December 01, 2015 , ... Live ... offer individual vision insurance plans on . The multi-carrier insurance exchange ... and review products, allowing consumers to compare, quote and match plans to meet ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... (Meso Foundation) released information for caregivers and held two webinars on topics of ... on demand free of charge at . , With a loved ...
(Date:11/30/2015)... ... November 30, 2015 , ... Thermi™, a ... to announce that its ThermiRFR temperature controlled radiofrequency platform has received CE marking ... radiofrequency platform which uses temperature as a clinical endpoint. The technology has ...
(Date:11/30/2015)... Fla. (PRWEB) , ... November 30, 2015 , ... ... opened the driverless vehicle experience this summer, ushering in a new era of ... percent driverless and electric shuttle, will continue to offer guests an up-close look ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 1, 2015 Express Scripts (NASDAQ: ESRX ) ... IMMY ) to drive access to a low-cost alternative to ... toxoplasmosis that has been recently priced out of reach for ... systems. --> --> Imprimis ... (a form of folic acid) for $1 per capsule for people ...
(Date:11/30/2015)... 2015 Die MEDTEC Japan ... für Entwicklung und Herstellung medizinischer Geräte, ... 2016 in Tokyo ... Foto:- Foto: ... Logo: --> ...
(Date:11/30/2015)... , December 1, 2015 ... adds "Endometriosis - Pipeline Review, H2 ... overview on therapeutic pipeline of Endometriosis and ... effective counter strategies to gain competitive advantage. ... targets and MOAs to produce first-in-class and ...
Breaking Medicine Technology: